Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.48 |
| ▸ | SMO | Q99835 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | TYK2 | P29597 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7083630 | 0.79 | TUBB4A (0.53) | TRPV1SMONPC1RAB9AALDH1A1 | |
| SCHEMBL7083634 | 0.79 | TUBB4A (0.53) | TRPV1SMONPC1RAB9AALDH1A1 | |
| SCHEMBL7086631 | 0.79 | NPC1 (0.54) | SMN1; SMN2NPC1RAB9A | |
| SCHEMBL7133291 | 0.78 | NPC1 (0.56) | TRPV1KDM4ESMN1; SMN2NPC1RAB9A | |
| SCHEMBL6792746 | 0.78 | PTGS1 (0.57) | SMN1; SMN2NPC1RAB9A | |
| SCHEMBL7087226 | 0.77 | SMO (0.49) | TRPV1SMOSORT1EGLN1ALDH1A1 | |
| SCHEMBL7084038 | 0.77 | NTRK1 (0.43) | SMOSORT1ALDH1A1 | |
| SCHEMBL7080705 | 0.76 | SMO (0.49) | TRPV1SMOGAASORT1EGLN1 | |
| SCHEMBL7087379 | 0.76 | RXFP1 (0.57) | TRPV1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL7079809 | 0.75 | CHRNB2 (0.45) | TRPV1SMOEGLN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | APOB, APOL1, SCARB1 | TRPV1 3714/4885SMO 2094/4885JAK2 2198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.